Therapeutic Insights
Filter News
Found 750 articles
-
Otsuka Pharmaceutical and Lundbeck Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer’s Dementia Treated with Brexpiprazole
6/27/2022
Results from a Phase 3 clinical study for treatment of agitation in patients with Alzheimer’s dementia showed that patients treated with brexpiprazole had a statistically significantly greater reduction in agitation compared to placebo.
-
CORRECTING and REPLACING Otsuka Pharmaceutical and Lundbeck Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer’s Dementia Treated with Brexpiprazole
6/27/2022
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announce positive results of the Phase 3 clinical trial of brexpiprazole in the treatment of agitation in patients with Alzheimer's dementia.
-
ALK begins clinical trial of its SLIT-tablet for the treatment of peanut allergy
6/27/2022
ALK announced that it is initiating Phase I clinical development of its investigational SLIT-tablet for the treatment of peanut allergy.
-
BiomX Announces Dosing of the First Two Patients in Phase 1b/2a Study of BX004 for Treatment of Chronic Respiratory Infections in Patients with Cystic Fibrosis
6/27/2022
BiomX Inc., a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announced the dosing of the first two patients in the Company’s Phase 1b/2a study evaluating BX004 for the treatment of chronic respiratory infections in patients with cystic fibrosis.
-
The Boston University School of Medicine has unraveled details about a known genetic component for the development of Alzheimer’s disease (AD): the APOE4 gene.
-
Researchers at the University of California, San Diego published promising preclinical work on a new combination therapy to treat colon cancer.
-
Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
6/22/2022
Primary endpoint of change in biomarker ERP P300 latency was not statistically significant for the full study population as combination of fosgonimeton and standard-of-care (AChEIs) given together showed potential diminished effect of fosgonimeton.
-
Alpha Cognition Announces Positive Results from Pivotal Study with ALPHA-1062 in Development for Alzheimer’s Disease
6/22/2022
Alpha Cognition Inc. today announced positive results from its pivotal bioequivalence study with ALPHA-1062, a proprietary, delayed release oral tablet formulation in development for the treatment of mild to moderate Alzheimer’s Disease (AD).
-
First Patient Included in AlzeCure's Phase II Clinical Trial in Neuropathic Pain with Non-opioid ACD440
6/21/2022
AlzeCure Pharma AB, a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, announced that the first patient has been included in a Phase II clinical trial with ACD440, the leading non-opioid drug candidate in the Painless platform which is being developed for peripheral neuropathic pain.
-
Acadia Pharmaceuticals Announces Outcome of FDA Advisory Committee for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis
6/18/2022
Acadia Pharmaceuticals Announces Outcome of FDA Advisory Committee for NUPLAZID ® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis.
-
The trial evaluated crenezumab’s ability to slow Alzheimer’s disease in cognitively unimpaired people with a specific gene mutation that causes early-onset Alzheimer’s disease.
-
Genentech Provides Update on Alzheimer’s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease
6/16/2022
Genentech, a member of the Roche Group, together with Banner Alzheimer’s Institute, announced results from the Alzheimer’s Prevention Initiative Autosomal Dominant Alzheimer's Disease Colombia Trial.
-
Landmark Alzheimer's Prevention Trial Unable to Show Significantly Slower Cognitive Decline in Inherited Form of Disease
6/16/2022
A precedent-setting prevention trial in Colombia has found that the investigational medicine crenezumab did not slow or prevent decline in cognition or memory for cognitively healthy people with a rare genetic mutation that causes early-onset Autosomal Dominant Alzheimer's Disease.
-
Study Plan of AlzeCure’s Phase II Clinical Study in Neuropathic Pain with Non-Opioid ACD440 Now Available
6/15/2022
AlzeCure Pharma AB announced that the study plan for the planned Phase II clinical study in neuropathic pain with ACD440, the leading non-opioid drug candidate in the Painless platform, is now available on ClinicalTrials.gov.
-
Jupiter Neurosciences, Inc. Announces Journal of Alzheimer's Disease Publication Highlighting use of JOTROL™
6/14/2022
Pre-clinical proof-of-concept demonstrated in a disease model.
-
Actinogen Announces Phase 2 Trials in Alzheimer's Disease and Depression
6/14/2022
Actinogen Medical Limited recently announced positive results for Part A of its two-part double-blind placebo-controlled XanaMIA dose-ranging trial, which confirmed Xanamem's ability to rapidly enhance attention and working memory.
-
Startup Vitalunga creates novel oral drug to enable disease-free aging; pre-clinical studies expected to begin in near future
6/13/2022
Vitalunga, the biotech startup based on the research led by Professor Einav Gross and Professor Shmuel Ben-Sasson of The Hebrew University's Faculty of Medicine, has developed a novel oral drug that aims to treat and prevent aging-related diseases such as Alzheimer's and Parkinson's.
-
Diadem Partners with Dementias Platform UK to Advance Diagnosis and Treatment of Alzheimer's Disease
6/13/2022
Diadem SpA, a company developing AlzoSure® Predict, the first blood-based test for the early prediction of progression to Alzheimer's disease, announced that is has joined Dementias Platform UK as a corporate partner.
-
Greg Grunberg, who has appeared in multiple Star Wars projects, has partnered with Jazz Pharmaceuticals to bring "The Care Giver", a video web series, to life.
-
Seelos Therapeutics announced in vitro data Thursday supporting its gene therapy, SLS-004. SLS-004 is intended for the treatment of dementia with Lewy bodies (DLB).